OXiGENE, Inc. Names John A. Kollins as Chief Executive Officer
October 23, 2008 02:00 ET
|
Mateon Therapeutics
WALTHAM, Mass., Oct. 23, 2008 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN) announced today that its Board of Directors has appointed John A. Kollins, the Company's current Chief...
OXiGENE Announces Clinical Trials Interim Data Update to be Presented At the 12th Biennial Meeting of the International Gynecologic Cancer Society
October 21, 2008 02:00 ET
|
Mateon Therapeutics
WALTHAM, Mass., Oct. 21, 2008 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye...
OXiGENE Announces Strategic Collaboration With Symphony Capital
October 01, 2008 02:00 ET
|
Mateon Therapeutics
WALTHAM, Mass., Oct. 1, 2008 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye...
ZYBRESTAT Named One of the 10 Most Interesting Oncology Projects Available for Partnering by Windhover
September 04, 2008 02:00 ET
|
Mateon Therapeutics
WALTHAM, Mass., Sept. 4, 2008 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), (XSSE:OXGN) today announced that ZYBRESTAT(tm) (fosbretabulin), the company's lead therapeutic product candidate, has...
OXiGENE Reports Second Quarter 2008 Results
August 04, 2008 02:00 ET
|
Mateon Therapeutics
WALTHAM, Mass., Aug. 4, 2008 (PRIME NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye...
OXiGENE Announces Second Quarter 2008 Earnings Conference Call and Webcast
July 28, 2008 02:00 ET
|
Mateon Therapeutics
WALTHAM, Mass., July 28, 2008 (PRIME NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye...
OXiGENE Announces Clinical Trials Data to be Presented At the 7th International Conference On Head and Neck Cancer
July 17, 2008 02:00 ET
|
Mateon Therapeutics
WALTHAM, Mass., July 17, 2008 (PRIME NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye...
OXiGENE Promotes Senior Executive
July 15, 2008 02:00 ET
|
Mateon Therapeutics
WALTHAM, Mass., July 15, 2008 (PRIME NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye...
OXiGENE Announces Clinical Trials Data to be Presented At the 2008 Annual Meeting of the American Society of Clinical Oncology
May 28, 2008 02:00 ET
|
Mateon Therapeutics
WALTHAM, Mass., May 28, 2008 (PRIME NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye...
OXiGENE Reports First Quarter 2008 Results
May 05, 2008 02:00 ET
|
Mateon Therapeutics
WALTHAM, Mass., May 5, 2008 (PRIME NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...